
Journal of Medicinal Chemistry p. 652 - 658 (1987)
Update date:2022-08-05
Topics: in vivo Redox Chemistry
Atwell, Graham J.
Rewcastle, Gordon W.
Baguley, Bruce C.
Denny, William A.
Structure-activity relationships for a series of acridine-substituted 3'-N(CH3)2 derivatives of the clinical antileukemic drug amsacrine (1) are reported.The parent (unsubstituted) compound 3 has activity against the Lewis lung solid tumor that is superior to amsacrine(1), the new clinical amsacrine analogue 4, and the recently developed 3'-NHCH3 derivative 2.Although the compounds generally bind less well to DNA and are less dose potent in vivo than either their amsacrine (3'-OCH3) or 3'-NHCH3 analogues, they show very high levels of antitumor activity, with the 4-OCH3 derivative capable of effecting 100percent cures of the Lewis lung solid tumor.The broad structure-activity relationships for acridine substitution more closely resemble those of the amsacrine than the 3'-NHCH3 series, with 4-substituted and 4,5-disubstituted compounds showing the highest activity.
View MoreDongying J&M Chemical Co., Ltd,
Contact:546-8551108
Address:Room 1219, Zisheng Mansion, Zibo Road, Dongying, Shandong, China
Shandong Yubin Chemical CO.,LTD
website:http://www.yukaichem.com/en.html
Contact:+86-536-8865336
Address:binhai economic development zone,262737 shangdong,china
Contact:86-27-84888681
Address:Wuhan economic & technology development zone
Contact:+86-0760-85282375
Address:zhongjing road,zhongshan torch hi-tech industrial development zone
Taizhou Elitechemie MediPharma Technology Co.,Ltd.
Contact:+86-523-86810021
Address:Building G14,NO.1 Avenue,China Medical City, Taizhou, Jiangsu,China
Doi:10.1016/j.tetlet.2016.06.036
(2016)Doi:10.1002/ejoc.202000066
(2020)Doi:10.1016/j.bmc.2006.02.021
(2006)Doi:10.1016/S0040-4039(00)71988-5
(1975)Doi:10.1021/ol034736n
(2003)Doi:10.1021/jo00908a023
(1975)